Ma L - Search Results

1

A comprehensive review on DCN1 protein, inhibitors and their therapeutic applications.

He Z, Yuan Z, Yang F, Zhang J, Zhao W, Qin T, Zheng X, Ma L. He Z, et al. Among authors: ma l. Int J Biol Macromol. 2024 Oct;277(Pt 4):134541. doi: 10.1016/j.ijbiomac.2024.134541. Epub 2024 Aug 5. Int J Biol Macromol. 2024. PMID: 39111501 Review.

2

Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway.

Cao Y, Yang P, Yang Y, Lin Z, Fan Z, Wei X, Yan L, Li Y, He Z, Ma L, Xu H, Wu C. Cao Y, et al. Among authors: ma l. Eur J Med Chem. 2023 May 5;251:115250. doi: 10.1016/j.ejmech.2023.115250. Epub 2023 Mar 11. Eur J Med Chem. 2023. PMID: 36931124

3

Targeting cullin neddylation for cancer and fibrotic diseases.

He ZX, Yang WG, Zengyangzong D, Gao G, Zhang Q, Liu HM, Zhao W, Ma LY. He ZX, et al. Theranostics. 2023 Sep 4;13(14):5017-5056. doi: 10.7150/thno.78876. eCollection 2023. Theranostics. 2023. PMID: 37771770 Free PMC article. Review.

4

Innovative medicinal chemistry strategies for enhancing drug solubility.

He Z, Yang W, Yang F, Zhang J, Ma L. He Z, et al. Among authors: ma l. Eur J Med Chem. 2024 Dec 5;279:116842. doi: 10.1016/j.ejmech.2024.116842. Epub 2024 Sep 6. Eur J Med Chem. 2024. PMID: 39260319 Review.

5

Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review.

Liu ZQ, Zhang Q, Liu YL, Yu XQ, Chui RH, Zhang LL, Zhao B, Ma LY. Liu ZQ, et al. Bioorg Med Chem. 2024 Sep 1;111:117847. doi: 10.1016/j.bmc.2024.117847. Epub 2024 Jul 28. Bioorg Med Chem. 2024. PMID: 39121679 Review.

6

Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors.

Li Z, Yuan Y, Wang P, Zhang Z, Ma H, Sun Y, Zhang X, Li X, Qiao Y, Zhang F, Su Y, Song J, Xie Z, Li L, Ma L, Ma J, Zhang Z. Li Z, et al. Among authors: ma l, ma j, ma h. Eur J Med Chem. 2023 May 5;253:115321. doi: 10.1016/j.ejmech.2023.115321. Epub 2023 Mar 30. Eur J Med Chem. 2023. PMID: 37037137

7

EZH2 serves as a promising therapeutic target for fibrosis.

Zhang Q, Wu YX, Yu XQ, Zhang BY, Ma LY. Zhang Q, et al. Bioorg Chem. 2023 Aug;137:106578. doi: 10.1016/j.bioorg.2023.106578. Epub 2023 May 3. Bioorg Chem. 2023. PMID: 37156135 Review.

8

Identification of a novel pyridine derivative with inhibitory activity against ovarian cancer progression in vivo and in vitro.

Si L, Lai T, Zhao J, Jin Y, Qi M, Li M, Fu H, Shi X, Ma L, Guo R. Si L, et al. Among authors: ma l. Front Pharmacol. 2022 Nov 18;13:1064485. doi: 10.3389/fphar.2022.1064485. eCollection 2022. Front Pharmacol. 2022. PMID: 36467091 Free PMC article.

9

Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance.

Cao Y, Wu C, Ma L. Cao Y, et al. Among authors: ma l. J Biochem Mol Toxicol. 2024 Jan;38(1):e23587. doi: 10.1002/jbt.23587. Epub 2023 Nov 28. J Biochem Mol Toxicol. 2024. PMID: 38014925 Review.

10

Editorial: New insights into post-translational modification of proteins and immune regulation in carcinogenesis, heart disease, neurodegenerative disorders, and allergic diseases.

Li Z, Ma L. Li Z, et al. Among authors: ma l. Front Pharmacol. 2023 Nov 30;14:1334429. doi: 10.3389/fphar.2023.1334429. eCollection 2023. Front Pharmacol. 2023. PMID: 38099143 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,851 results

Search Page

Filters